Core Viewpoint - The stock price of Pioneer Pharma Biotechnology (0399.HK) experienced a significant drop of 22.12% to HKD 0.405, marking a nearly two-month low since July 21 [1] Group 1: Company Announcement - Pioneer Pharma announced a placement agreement with China Northern Securities Group, set for August 21, 2025, to issue up to 145 million shares at a placement price of HKD 0.415 per share [1] - The board declared that the placement agreement became invalid as the conditions precedent were not met by September 11, 2025, resulting in the cancellation of the placement [1] Group 2: Financial Implications - The company had previously announced on August 21 that it aimed to raise HKD 58.825 million from the placement of 145 million shares, with the proceeds intended for funding the development of its blockchain technology business [1] - Following the announcement of the placement on August 22, the stock surged by 10.87% [1]

Core Viewpoint - The stock of Pioneer Pharma Biotechnology (00399) has dropped over 19% following the expiration of a share placement agreement aimed at raising HKD 60.18 million, which failed to meet its conditions by the deadline of September 11 [1] Group 1: Stock Performance - As of the report, Pioneer Pharma's stock is down 19.23%, trading at HKD 0.42, with a trading volume of HKD 16.28 million [1] Group 2: Share Placement Agreement - The company announced that the share placement agreement for a maximum of 145 million new shares has become invalid due to unmet conditions [1] - The board believes that the failure of the placement agreement will not have any significant adverse impact on the company's current operations and financial status [1] Group 3: Previous Announcements - On August 21, the company had previously announced a plan to place shares at HKD 0.415 each, aiming to raise approximately HKD 58.83 million, which was intended for funding the development of blockchain technology [1]

Core Viewpoint - The company, Pioneer Pharmaceuticals Biotechnology (00399), has announced a placement agreement to issue up to 145 million shares at a price of HKD 0.415 per share, which represents a discount of approximately 9.78% from the closing price of HKD 0.46 on August 21, 2025 [1] Group 1 - The placement is expected to involve at least six independent third-party subscribers [1] - If all shares are fully placed, the total proceeds from the placement will be approximately HKD 60.175 million [1] - After deducting related expenses of about HKD 1.35 million, the estimated net proceeds will be around HKD 58.825 million [1] Group 2 - The net proceeds from the placement are intended to be used entirely for funding the company's blockchain technology business development [1]